400 ATLANTIC STREET, SUITE 500, STAMFORD, CT
Market cap: $8.1M (4/14/2025)
Price: $5.32
Retention Compensation Approved for Executive Officers at Tvardi Therapeutics
Investor Presentation
Earnings Release
Provides Update on Preliminary Data from Phase 2 REVERT Trial in Idiopathic Pulmonary Fibrosis
Announces Second Quarter 2025 Results and Provides Business Update
Changes in Board, Management or Compensation
Other Events
Announces Completion of Enrollment in Phase 2 Clinical Trial of TTI-101 in Idiopathic Pulmonary Fibrosis
Q3
Q2
Q1
FY 2024
FY 2023
Prospectus filed pursuant to Rule 424(b)(3)
Registration Statement for Securities to be Offered to Employees
Amended Registration Statement for Securities
S-1
Prospectus Filed Pursuant to Rule 425
Effectiveness Notice
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Statement of Changes in Beneficial Ownership
Amended Schedule 13G - Ownership Report
Amended Statement of Changes in Beneficial Ownership